SummaryRMgm-5225
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 36126089 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | unknown |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Gabelich JA, Ingmundson A |
Name Group/Department | Molecular Parasitology |
Name Institute | Humboldt University |
City | Berlin |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5225 |
Principal name | ipis2- |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | (Slightly) reduced growth/multiplication rate of asexual blood stages. Schizonts show reduced sequestration in inner capillaries of organs and are detected in the peripheral blood circulation (fifteen-fold more schizonts in the peripheral blood compared to wild type). Evidence for reduced binding to host CD36 in in-vitro assays. |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not different from wild type |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation Phenotype Normal/wild-type-like sporozoite formation and liver stage development. - IPIS2 and IPIS3 localizes to punctate structures in the cytoplasm of infected red blood cells In order to determine if the putative orthologs from P. vivax also targeted the membrane structures in the cytoplasm of Plasmodium-infected red blood cells, we generated P. berghei lines that expressed HA-tagged PvTRAg8, the syntenic P. vivax ortholog of IPIS2 (PVP01_0532600) or HA-tagged PvTRAg2, which shares similarity to IPIS3 (PVP01_0202200). These genes were integrated into the P. berghei genome such that they are expressed under the control of the IPIS2 or IPIS3 promoters, respectively. Both PvTRAg8-HA and PvTRAg2-HA are exported efficiently by P. berghei and localize to discrete structures in the cytoplasm of infected erythrocytes. Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0524300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | Not available | ||||||||||||||||||||||||
Gene product | tryptophan-rich protein | ||||||||||||||||||||||||
Gene product: Alternative name | IPIS2, intra-erythrocytic Plasmodium-induced structure protein 2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | 5-fluorocytosine (5-FC) | ||||||||||||||||||||||||
Additional remarks genetic modification | For the construction of the plasmids used for endogenous C-terminal mCherry tagging, regions containing the IPIS2, IPIS3 or PBANKA_1400700 genes were amplified from P. berghei genomic DNA using the respective primers and integrated into the SacII and XbaI sites of the B3D+mCherry plasmid. The sequences of PvTRAg8 and PvTRAg2 were codon-optimized synthesized (GenScript) and cloned into the NotI and SpeI sites of b3D.DT^H.^D. The 5’ and 3’ untranslated regions of the IPIS2 and IPIS3 genes were cloned into the GOMO-GFP luciferase vector using the respective primers containing SacII and NotI sites and the XhoI and KpnI sites, respectively, in order to delete IPIS2 and IPIS3 via double homologous recombination. Clonal lines of ipis2-[GFP-Luc;mCherry], ipis3-[GFP-Luc;mCherry], and ipis2-ipis3-[GFP-Luc;mCherry] were generated by FACS sorting mCherry+GFP+ parasites and injecting them into new recipient mice. PCR was used to confirm genotypes. To remove the DHFR-resistance from the knockout lines and concurrently select for parasites encoding single fluorescent reporters, the knockout lines were put under selective pressure for five days with 1.5mg/ml 5-fluorocytosine (5-FC) to the mouse drinking water, which was administered fresh daily and protected from light. Isogenic clonal lines were generated by FACS sorting parasites that expressed only mCherry or GFP-luciferase. This process yielded the lines ipis2-[GFP-Luc; PyrS] and ipis3-[GFP-Luc; PyrS]. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |